-
Mashup Score: 15
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the implications of the FDA approval of imetelstat for transfusion-dependent anemia in MDS.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 26
Dr. Amer Zeidan presents interim Phase 1a results from the KOMET-007 trial, demonstrating the safety and robust clinical activity of ziftomenib combined with intensive chemotherapy (7+3) in newly diagnosed adverse-risk NPM1-mutated and KMT2A-rearranged acute myeloid leukemia, highlighting high response rates and promising survival outcomes.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet-
Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007 https://t.co/mM3kvcTECz via @onclive
-
-
Mashup Score: 33How I treat iron overload in adult MDS - 27 day(s) ago
It has long been recognized that iron overload is toxic and that diagnosis and management of iron overload in patients with hematological disorders are com
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
RT @BloodJournal: How I treat iron overload in adult MDS https://t.co/gqk0XYqwA4 #hematologicdisorders #howitreat #myeloidneoplasia #redcel…
-
-
Mashup Score: 33How I treat iron overload in adult MDS - 27 day(s) ago
It has long been recognized that iron overload is toxic and that diagnosis and management of iron overload in patients with hematological disorders are com
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
RT @BloodJournal: How I treat iron overload in adult MDS https://t.co/gqk0XYqwA4 #hematologicdisorders #howitreat #myeloidneoplasia #redcel…
-
-
Mashup Score: 20Early Findings on Ziftomenib With Chemotherapy in AML From KOMET-007 Trial | Blood Cancers Today - 1 month(s) ago
Ziftomenib plus standard cytarabine and daunorubicin chemotherapy was well tolerated with consistent safety and continued to show robust clinical activity in NPM1-mutated AML.
Source: bloodcancerstoday.comCategories: General Medicine News, Hem/OncsTweet-
Early Findings on Ziftomenib With Chemotherapy in AML From KOMET-007 Trial https://t.co/7s4Iksjmue
-
-
Mashup Score: 44Advancing Drug Development in Myelodysplastic Syndromes - 1 month(s) ago
Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of all
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
An very important white paper summarizing thoughts from different stakeholders including academia, FDA, and others from a workshop that debated every aspect of Drug Development in #MDSsm kudos to authors led by myeloid malignancy rising star @dralainmina https://t.co/ko524m9JRC
-
-
Mashup Score: 44Advancing Drug Development in Myelodysplastic Syndromes - 1 month(s) ago
Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of all
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
An very important white paper summarizing thoughts from different stakeholders including academia, FDA, and others from a workshop that debated every aspect of Drug Development in #MDSsm kudos to authors led by myeloid malignancy rising star @dralainmina https://t.co/ko524m9JRC
-
-
Mashup Score: 38Advancing Drug Development in Myelodysplastic Syndromes - 2 month(s) ago
Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of all
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
An very important white paper summarizing thoughts from different stakeholders including academia, FDA, and others from a workshop that debated every aspect of Drug Development in #MDSsm kudos to authors led by myeloid malignancy rising star @dralainmina https://t.co/ko524m9JRC
-
-
Mashup Score: 5
The WHO and International Consensus Classification 2022 classifications of myelodysplastic syndromes enhance diagnostic precision and refine decision-making processes in these diseases. However, some discrepancies still exist and potentially cause inconsistency in their adoption in a clinical setting. We adopted a data-driven approach to provide a harmonisation between these two classification systems. We investigated the importance of genomic features and their effect on the cluster assignment process to define harmonised entity labels.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
@beatalleukemia @ic_MDS This work follows our recent international, data-driven approach to harmonization of #MDSsm classification schema which would also improve consistency of trial eligibility https://t.co/x56ILFnCU2
-
-
Mashup Score: 19Early Findings on Ziftomenib With Chemotherapy in AML From KOMET-007 Trial | Blood Cancers Today - 2 month(s) ago
Ziftomenib plus standard cytarabine and daunorubicin chemotherapy was well tolerated with consistent safety and continued to show robust clinical activity in NPM1-mutated AML.
Source: bloodcancerstoday.comCategories: General Medicine News, Hem/OncsTweet-
Early Findings on Ziftomenib With Chemotherapy in AML From KOMET-007 Trial https://t.co/7s4Iksjmue
-
Where Imetelstat Fits Into the Paradigm for Transfusion-Dependent Anemia in #MDSsm https://t.co/mxl104eltU via @onclive